Home
/ Tikomed
/ Competitors

Tikomed Competitors and Similar CompaniesClear all

Tikomed's competitors and similar companies include Kangstem Biotech, Phyton Biotech, Ventus Therapeutics and Sanofi.

	Tikomed Tikomed is a company that develops treatments for patients with severe and life-threatening conditions.	Kangstem Biotech Kangstem Biotech (강스템바이오텍) is a biopharmaceutical company that focuses on blood-derived stem cell therapy.	Phyton Biotech Phyton Biotech is a company that specializes in the pharmaceutical plant cell fermentation (PCF) technology.	Ventus Therapeutics Ventus Therapeutics is a company that develops small molecule therapeutics intended to target key innate immune pathways.	Sanofi Sanofi is a healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions.
Founding Date	Founding Date 2002	Founding Date 2010	Founding Date 2009	Founding Date N/A	Founding Date 1994
Type	Type Private	Type Public	Type Private	Type Private	Type Public
Tags	Tags Healthcare biotech drug development life sciences pharma therapy	Tags Healthcare biotech drug development life sciences pharma therapy	Tags Healthcare biotech drug development life sciences pharma therapy	Tags Healthcare biotech drug development life sciences pharma therapy	Tags Healthcare biotech drug development life sciences pharma therapy
Locations	Locations Viken, SE HQ	Locations KR HQ	Locations Delta, CA HQ Ahrensburg, DE	Locations Montréal, CA HQ Waltham, US	Locations Paris, FR HQ Hydra, DZ Buenos Aires, AR Macquarie Park, AU Melbourne, AU Virginia, AU Wien, AT see more
Employees	Employees 8	Employees 97	Employees 1232% increase	Employees 952% increase	Employees 82,878
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) ₩7.7b (FY, 2024)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) €45.4b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods ₩838.6m (FY, 2024)	Cost of goods N/A	Cost of goods N/A	Cost of goods €11.6b (FY, 2025)
Gross profit	Gross profit N/A	Gross profit ₩7.1b (FY, 2024)	Gross profit N/A	Gross profit N/A	Gross profit €37.6b (FY, 2025)
Net income	Net income N/A	Net income (₩7.1b) (FY, 2024)	Net income N/A	Net income N/A	Net income €8b (FY, 2025)
Funding
Total funding raised	Total funding raised N/A	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 160m	Total funding raised $ 310m